Metagenomics Market (2025-2032)
The Metagenomics Market was valued at $2.43 billion in 2024. This market is expected to reach $7.78 billion by 2032 from an estimated $2.80 billion in 2025, at a CAGR of 15.8% during the forecast period from 2025 to 2032. Metagenomics Market Size & Forecast The growth of the Metagenomics Market is
- Published
- Jan 2025
- Pages
- 155
- Format
- PDF + Excel
- Report ID
- MR-1444
- Base year
- 2024
- 2024 · BASELINE
- $2.43B
- 2032
- $7.78B
- CAGR 2025–2032
- 15.8%
2024 baseline · 2025–2032 forecast at 15.8% CAGR · hover a bar for the value
Key highlights
By Offering: The Consumables Segment Dominated the Metagenomics Market in 2024.
By Technology: The 16S Sequencing Segment Dominated the Metagenomics Market in 2024.
By Application: Environmental Applications Dominated the Metagenomics Market in 2024.
By Geography: North America Dominated the Metagenomics Market in 2024.
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | 156 |
| Format | |
| Forecast Period | 2025-2032 |
| Base Year | 2024 |
| CAGR | 15.8% |
| Market Size in 2025 | $2.8 billion |
| Market Size in 2032 | $7.78 Billion |
| Segments Covered | By Offering · Consumables · Instruments · Software & Services · Sequencing & Data Analysis Services · By Technology · 16S Sequencing · Shotgun Metagenomic Sequencing · Whole Genome Sequencing · Other Technologies · (Note: Other technologies include targeted microbial sequencing, meta transcriptome sequencing, and pyrosequencing.) · By Application · Environmental Applications · Clinical Diagnostics · Drug Discovery · Biotechnology · Other Applications · (Note: Other applications include food & nutrition, agriculture & soil health, marine microbiomes, and extremophiles.) |
| Countries Covered | North America (U.S., Canada), Europe (Germany, U.K., France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, Rest of APAC), Latin America, and the Middle East & Africa |
| Key Companies Profiled | Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pacific Biosciences of California Inc. (U.S.), QIAGEN N.V. (Netherlands), Revvity, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Takara Bio, Inc. (Japan), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), 10X GENOMICS, INC. (U.S.), Promega Corporation (U.S.), Cantata Bio, LLC, and Zymo Research Corporation (U.S.). |
Report overview
Segments covered: offering, technology, application. Regions: North America, Europe, Asia-Pacific.
The growth of the Metagenomics Market is primarily driven by decreasing sequencing cost, increasing focus on Agri genomics, expansion of F&B industry, and surge in genome mapping programs. Furthermore, rising adoption of bioinformatics and genomic data management solutions and government initiatives supporting large-scale genomic sequencing projects are expected to generate growth opportunities for the stakeholders in this Market.
Market dynamics
3 factors across 2 forcesGovernment Initiatives Supporting Large-scale Genomic Sequencing Projects
Large-scale genomic sequencing projects have significantly boosted the metagenomics market by providing vast amounts of data that highlight the importance of studying complex microbial communities. These projects, which involve sequencing the genetic material of entire ecosystems, have expanded the scope of metagenomics, leading to rapid growth in both research and commercial applications.
As these initiatives expand, they create increased demand for metagenomic tools and solutions to analyze, interpret, and apply vast amounts of genomic data. The collaboration between governments, research institutions, and industry players further enhances innovation and adoption of metagenomics technologies in healthcare, environmental monitoring, and drug development. For instance;
- In June 2023, Oxford Nanopore Technologies Plc. (U.K.) collaborated with Zheijiang Digena Diagnostic Technology Co. Ltd (China) and Wuhan Dgensee Clinical Laboratory Co., Ltd (China) to develop nanopore sequencing as an IVD test for metagenomics, infectious disease, oncology, and other conditions
- In September 2020, the U.K. government published ‘Genome UK, the Future of Healthcare,’ a 10-year strategy to create the most advanced genomic healthcare system.
- in October 2022, NHS England published its first genomics strategy for embedding genomics in the NHS for the next five years. NHS England also announced that during 2023- 2024, the NHS will establish Genomic Networks of Excellence to bring together system partners to deliver genomic research from bench to bedside.
- In April 2022, Genomic Medicine Sweden and the Danish National Genome Center signed an agreement to advance genomics and precision medicine and its implementation in healthcare.
As these projects continue to evolve, they will further expand the scope and impact of metagenomics, creating new opportunities for research, innovation, and commercialization.
Table of contents
11 chapters · 91 sections · 155 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Offering | Consumables | — |
| By Application | Environmental Application | Drug discovery |
By Offering
- The consumables segment is expected to account for the largest share of 52.4% of the global metagenomics market.
- Technological advancements in reagents and kits, the development of user-friendly kits, and the adoption of metagenomics kits in research laboratories are factors contributing to the segment’s large share.
- Assay kits are pre-packaged sets of materials and reagents used for performing tests.
- Using these kits requires minimal training, making them ideal for use in settings lacking trained laboratory technicians and lab instruments.
- The recurring use of consumables, the rising demand for microbial gene profiling, and the increasing applications of metagenomics in human microbiome mapping and drug discovery are driving the demand for consumables.
- The use of metagenomics kits is also increasing gradually in diagnostic settings.
- For instance, in March 2024, Microba Life Sciences (Australia) launched the MetaPanel.
- The panel is a metagenomic diagnostic test for diagnosing common and difficult-to-identify gastrointestinal pathogens causing infection.
- The panel launch was a part of the company's agreement with Sonic Healthcare Limited (Australia) to provide the company's advanced gastrointestinal pathogen test, MetaPanel, in Australia.
By Application
- Environmental Application segment is expected to Dominate the Metagenomics Market
- The environmental applications segment is expected to account for the largest share of the Metagenomics Market.
- The large share of this segment is attributed to rapid industrialization, urbanization, and agricultural activities.
- Growing urbanization and industrialization have resulted in the production and release of a variety of harmful organic and inorganic pollutants into the environment.
- These harmful substances build up and survive for lengthy periods, degrading the surrounding environment.
- This creates a demand for metagenomic solutions for environmental research purposes.
- However, the drug discovery segment is expected to grow at the highest CAGR of during the forecast period of 2024 to 2031.
- The increasing usage by the researchers for discovering novel bioactive compounds and metabolic pathways, contributing to the development of new drugs as conventional culture-based methods lack the ability to capture the full microbial spectrum.
- These characteristics are particularly significant for discovering antibiotics to combat growing drug resistance.
- These factors contribute to the fastest growth of the segment.
Geographic analysis
North America
Largest shareIn 2024, North America is estimated to account for the largest share and highest growth of the global Metagenomics Market. The region’s large share of the Metagenomics Market is primarily attributed to High number of research institutes, universities, and organizations, and presence of key market players in the market. Furthermore, the growing focus on the development of personalized medicines and increasing research activities in the field of microbial genomics are driving the demand for metagenomics products in the region. Additionally, advancements in sequencing technology and declining cost of sequencing technology are further expected to drive the metagenomics market in the region. North America to Dominate the Metagenomics Market in 2024
Competitive landscape
- June 2024
Illumina Inc. launched integrated chemistry XLEAP-SBS into the reagents used with NextSeq 1000 and NextSeq 2000 Next-generation Sequencing (NGS) instruments to help improve sequencing procedures with faster run times and high output.
- April 2024
Oxford Nanopore Technologies collaborated with BugSeq (U.S.) a bioinformatics platform to deliver rapid and accurate analysis solution for microbiology labs. The aim is to gain insights from vast genomic data including pathogen identification and antimicrobial resistance profiling.
- January 2024
QIAGEN collaborated with Penn State University (U.S.) to develop a shared research and education facility for the fast-developing microbiome sciences. QIAGEN will provide instruments and solutions for the shared research and education facility at Huck Institutes (U.S.) to support the One Health Microbiome Center.
- September 2023
Pacific Biosciences collaborated with leading library preparation automation partners Hamilton (U.S.), Integra (India), Revvity (U.S.), and Tecan (Switzerland) to offer automated library prep workflows for whole genome sequencing. These protocols were made for PacBio’s Revio and Sequel II and IIe systems.
- February 2023
Bio-Rad partnered with Element Biosciences, Inc. (U.S.) to develop a new sequencing platform that uses the capabilities of the Bio-Rad SEQuoia RNA Sequencing Library Preparation portfolio on the Element AVITI Benchtop Sequencer.
- Illumina, Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- F. Hoffmann-La Roche Ltd · Switzerland
- Pacific Biosciences of California Inc. (U.S.)
- QIAGEN N.V. · Netherlands
- Revvity, Inc. (U.S.)
- Oxford Nanopore Technologies Plc. (U.K.)
- Takara Bio, Inc. · Japan
- Bio-Rad Laboratories, Inc. (U.S.)
- Agilent Technologies, Inc. (U.S.)
- 10X GENOMICS, INC. (U.S.)
- Promega Corporation (U.S.)
- Cantata Bio, LLC
- Zymo Research Corporation (U.S.)
Frequently asked questions
The Metagenomics Market was valued at $2.43 billion in 2024.
Cite this report
Meticulous Research. (2025). Metagenomics Market - Global Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MR-1444). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/metagenomics-market-6127